Interview with BioWorld

Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.


Dr James Garner discusses GDC-0084 interim efficacy data with Pitt Street Research

Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.


2019 Annual General Meeting Presentation Webcast

Kazia is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2019 AGM, together with questions and answers relating to the presentation.